The poster presentation is entitled "Cytotoxicity of novel alkylating anthraquinones in cells with DNA Nucleotide Excision Repair and DNA Mismatch Repair defects," and focuses on structure-activity studies on the company's novel technology for targeting and irreversibly binding to DNA / DNA processing enzymes. The studies reported in the poster were conducted at the Institute for Cancer Therapeutics at the University of Bradford, Bradford, United Kingdom (www.cancer.Brad.ac.uk) under the collaborative research agreement announced previously.
Somanata recently announced the company had signed a letter of intent to be acquired by Access Pharmaceuticals, Inc, (OTCBB:ACCP) an emerging oncology-focused biopharmaceutical company based in Dallas, Texas.
About Somanta Pharmaceuticals
Somanta Pharmaceuticals, Inc. ("Somanta") is a specialty oncology company with particular focus on in-licensing anti-cancer agents with substantial clinical data supporting safety and efficacy. To date, the Company has successfully in-licensed the rights to four products, each with a different mode of action and targeting eleven different cancer types.
Certain statements contained herein are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statem ents include, but are not limited to: risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and in Somanta's compounds under development in particular; the potential failure of Somanta's compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Somanta's compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Somanta's business, structure or projections; the development of competing products; uncertainties related to Somanta's dependence on third parties and partners; and those risks described in Somanta's filings with the SEC. Somanta disclaims any obligation to update these forward-looking statements.
Somanta Pharmaceuticals, Inc.
Terrance J. Bruggeman
Agamemnon A. Epenetos
President and Chief Executive Officer
011-44 207 631 4868